FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969798675> ?p ?o ?g. }

• W1969798675 endingPage "40" @default.
• W1969798675 startingPage "31" @default.
• W1969798675 abstract "Background. Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods. Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired pneumonia (HAP) due to gram-positive pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA). Patients were randomized 1:1 to telavancin (10 mg/kg every 24 h) or vancomycin (1 g every 12 h) for 7–21 days. The primary end point was clinical response at follow-up/test-of-cure visit. Results. A total of 1503 patients were randomized and received study medication (the all-treated population). In the pooled all-treated population, cure rates with telavancin versus vancomycin were 58.9% versus 59.5% (95% confidence interval [CI] for the difference, –5.6% to 4.3%). In the pooled clinically evaluable population (n = 654), cure rates were 82.4% with telavancin and 80.7% with vancomycin (95% CI for the difference, –4.3% to 7.7%). Treatment with telavancin achieved higher cure rates in patients with monomicrobial S. aureus infection and comparable cure rates in patients with MRSA infection; in patients with mixed gram-positive/gram-negative infections, cure rates were higher in the vancomycin group. Incidence and types of adverse events were comparable between the treatment groups. Mortality rates for telavancin-treated versus vancomycin-treated patients were 21.5% versus 16.6% (95% CI for the difference, –0.7% to 10.6%) for study 0015 and 18.5% versus 20.6% (95% CI for the difference, –7.8% to 3.5%) for study 0019. Increases in serum creatinine level were more common in the telavancin group (16% vs 10%). Conclusions. The primary end point of the studies was met, indicating that telavancin is noninferior to vancomycin on the basis of clinical response in the treatment of HAP due to gram-positive pathogens." @default.
• W1969798675 created "2016-06-24" @default.
• W1969798675 creator A5010409085 @default.
• W1969798675 creator A5010911816 @default.
• W1969798675 creator A5011326404 @default.
• W1969798675 creator A5019419595 @default.
• W1969798675 creator A5020757594 @default.
• W1969798675 creator A5021390343 @default.
• W1969798675 creator A5021984025 @default.
• W1969798675 creator A5022407641 @default.
• W1969798675 creator A5026604447 @default.
• W1969798675 creator A5027979379 @default.
• W1969798675 creator A5036750574 @default.
• W1969798675 creator A5039843606 @default.
• W1969798675 creator A5040562230 @default.
• W1969798675 creator A5054900639 @default.
• W1969798675 creator A5055361364 @default.
• W1969798675 creator A5058653363 @default.
• W1969798675 creator A5062306774 @default.
• W1969798675 creator A5062456693 @default.
• W1969798675 creator A5069349916 @default.
• W1969798675 creator A5075236355 @default.
• W1969798675 date "2011-01-01" @default.
• W1969798675 modified "2023-10-10" @default.
• W1969798675 title "Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens" @default.
• W1969798675 cites W147164691 @default.
• W1969798675 cites W1525117555 @default.
• W1969798675 cites W1966621081 @default.
• W1969798675 cites W1970492397 @default.
• W1969798675 cites W1986722533 @default.
• W1969798675 cites W2036934691 @default.
• W1969798675 cites W2070418581 @default.
• W1969798675 cites W2071637551 @default.
• W1969798675 cites W2112604687 @default.
• W1969798675 cites W2116900840 @default.
• W1969798675 cites W2123175723 @default.
• W1969798675 cites W2128076923 @default.
• W1969798675 cites W2129197867 @default.
• W1969798675 cites W2135191756 @default.
• W1969798675 cites W2147723850 @default.
• W1969798675 cites W2147914349 @default.
• W1969798675 cites W2161328469 @default.
• W1969798675 cites W2219714852 @default.
• W1969798675 cites W2770339944 @default.
• W1969798675 cites W4211194064 @default.
• W1969798675 cites W4294990605 @default.
• W1969798675 doi "https://doi.org/10.1093/cid/ciq031" @default.
• W1969798675 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3060890" @default.
• W1969798675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21148517" @default.
• W1969798675 hasPublicationYear "2011" @default.
• W1969798675 type Work @default.
• W1969798675 sameAs 1969798675 @default.
• W1969798675 citedByCount "235" @default.
• W1969798675 countsByYear W19697986752012 @default.
• W1969798675 countsByYear W19697986752013 @default.
• W1969798675 countsByYear W19697986752014 @default.
• W1969798675 countsByYear W19697986752015 @default.
• W1969798675 countsByYear W19697986752016 @default.
• W1969798675 countsByYear W19697986752017 @default.
• W1969798675 countsByYear W19697986752018 @default.
• W1969798675 countsByYear W19697986752019 @default.
• W1969798675 countsByYear W19697986752020 @default.
• W1969798675 countsByYear W19697986752021 @default.
• W1969798675 countsByYear W19697986752022 @default.
• W1969798675 countsByYear W19697986752023 @default.
• W1969798675 crossrefType "journal-article" @default.
• W1969798675 hasAuthorship W1969798675A5010409085 @default.
• W1969798675 hasAuthorship W1969798675A5010911816 @default.
• W1969798675 hasAuthorship W1969798675A5011326404 @default.
• W1969798675 hasAuthorship W1969798675A5019419595 @default.
• W1969798675 hasAuthorship W1969798675A5020757594 @default.
• W1969798675 hasAuthorship W1969798675A5021390343 @default.
• W1969798675 hasAuthorship W1969798675A5021984025 @default.
• W1969798675 hasAuthorship W1969798675A5022407641 @default.
• W1969798675 hasAuthorship W1969798675A5026604447 @default.
• W1969798675 hasAuthorship W1969798675A5027979379 @default.
• W1969798675 hasAuthorship W1969798675A5036750574 @default.
• W1969798675 hasAuthorship W1969798675A5039843606 @default.
• W1969798675 hasAuthorship W1969798675A5040562230 @default.
• W1969798675 hasAuthorship W1969798675A5054900639 @default.
• W1969798675 hasAuthorship W1969798675A5055361364 @default.
• W1969798675 hasAuthorship W1969798675A5058653363 @default.
• W1969798675 hasAuthorship W1969798675A5062306774 @default.
• W1969798675 hasAuthorship W1969798675A5062456693 @default.
• W1969798675 hasAuthorship W1969798675A5069349916 @default.
• W1969798675 hasAuthorship W1969798675A5075236355 @default.
• W1969798675 hasBestOaLocation W19697986751 @default.
• W1969798675 hasConcept C120665830 @default.
• W1969798675 hasConcept C121332964 @default.
• W1969798675 hasConcept C126322002 @default.
• W1969798675 hasConcept C141071460 @default.
• W1969798675 hasConcept C179755657 @default.
• W1969798675 hasConcept C2777052132 @default.
• W1969798675 hasConcept C2777914695 @default.
• W1969798675 hasConcept C2778980435 @default.
• W1969798675 hasConcept C2779489039 @default.
• W1969798675 hasConcept C2908647359 @default.
• W1969798675 hasConcept C44249647 @default.

• next